Skip to main content
Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
8.92
-0.50 (-5.31%)
At close: Apr 3, 2025, 4:00 PM
8.35
-0.57 (-6.39%)
Pre-market: Apr 4, 2025, 4:25 AM EDT

Oruka Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024
Period Ending
 Dec '24
Selling, General & Admin
14.25
Research & Development
81.01
Operating Expenses
95.26
Operating Income
-95.26
Interest Expense
-1.6
Interest & Investment Income
6.4
Other Non Operating Income (Expenses)
0
EBT Excluding Unusual Items
-90.46
Other Unusual Items
-0.87
Pretax Income
-91.34
Net Income
-91.34
Preferred Dividends & Other Adjustments
-20.39
Net Income to Common
-70.95
Shares Outstanding (Basic)
17
Shares Outstanding (Diluted)
17
EPS (Basic)
-4.23
EPS (Diluted)
-4.23
Free Cash Flow
-63.3
Free Cash Flow Per Share
-3.77
EBITDA
-95.23
D&A For EBITDA
0.03
EBIT
-95.26
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q